Michele Maio

List of Publications by Year
in descending order

232 papers	63,439 citations	8208 78 h-index	1285 231 g-index
254 all docs	254 docs citations	254 times ranked	51290 citing authors

#	Article	IF	Citations
1	The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma. Molecular Oncology, 2022, 16, 565-593.	2.1	11
2	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2022, 40, 127-137.	0.8	446
3	KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. European Journal of Cancer, 2022, 160, 1-11.	1.3	4
4	Pembrolizumab in Patients With Microsatellite Instabilityâ€“High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. Journal of Clinical Oncology, 2022, 40, 752-761.	0.8	189
5	Nivolumab plus ipilimumab in melanoma brain metastases. Lancet Oncology, The, 2022, 23, e53.	5.1	5
6	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemotherapy and Pharmacology, 2022, 89, 499-514.	1.1	7
7	Health-related quality of life in patients treated with pembrolizumab for microsatellite instabilityâ€“high/mismatch repairâ€“deficient advanced solid tumours: Results from the KEYNOTE-158 study. European Journal of Cancer, 2022, 169, 188-197.	1.3	3
8	SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines. European Journal of Cancer, 2022, 171, 143-149.	1.3	3
9	Abstract CT557: Phase 1/2 study of quavonlimab (Qmab) + pembrolizumab (pembro) in patients (pts) with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor. Cancer Research, 2022, 82, CT557-CT557.	0.4	2
10	Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients. , 2021, 9, e001167.		11
11	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 655-664.	5.1	37
12	Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.. Journal of Clinical Oncology, 2021, 39, 2565-2565.	0.8	4
13	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 643-654.	5.1	224
14	Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. Clinical Cancer Research, 2021, 27, 4737-4745.	3.2	35
15	A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. Journal of Experimental and Clinical Cancer Research, 2021, 40, 240.	3.5	3
16	Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!. European Journal of Cancer, 2021, 152, 155-164.	1.3	21
17	Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. Journal of Clinical Oncology, 2021, 39, 2914-2925.	0.8	55
18	Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. Lancet Respiratory Medicine,the, 2021, 9, 969-976.	5.2	29

#	Article	IF	Citations
19	Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix. European Journal of Cancer, 2021, 156, 119-121.	1.3	7
20	Perspectives of Immunotherapy in Advanced Melanoma: Combinations and Sequencing. , 2021, , 281-310.		0
21	COVID and Lung Cancer. Current Oncology Reports, 2021, 23, 134.	1.8	21
22	Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy. Epigenomes, 2021, 5, 27.	0.8	3
23	Adjuvant nivolumab versus ipilimumab in resected stage IIIBâ€“C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 1465-1477.	5.1	330
24	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. Journal of Clinical Oncology, 2020, 38, 3638-3651.	0.8	130
25	SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: Clinical course and outcome. European Journal of Cancer, 2020, 133, 1-3.	1.3	20
26	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
27	Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. Clinical Cancer Research, 2020, 26, 4201-4205.	3.2	30
28	Serafino Zappacosta: An Enlightened Mentor and Educator. Frontiers in Immunology, 2020, 11, 217.	2.2	1
29	Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival. Cancers, 2020, 12, 361.	1.7	19
30	Challenges in lung cancer therapy during the COVID-19 pandemic. Lancet Respiratory Medicine,the, 2020, 8, 542-544.	5.2	88
31	Abstract CT270: A randomized, multi-center, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/-PD-L1: The NIBIT-ML1 Study. , 2020, , .		4
32	Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy. Archives of Endocrinology and Metabolism, 2020, 64, 483-486.	0.3	13
33	Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy. Cell Death and Disease, 2020, 11, 392.	2.7	14
34	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. European Journal of Cancer, 2019, 119, 1-10.	1.3	132
35	The future of mesothelioma treatment: time to shift gear. Lancet Respiratory Medicine,the, 2019, 7, 554-555.	5.2	2
36	Immunotherapy of brain metastases: breaking a â€œdogmaâ€• Journal of Experimental and Clinical Cancer Research, 2019, 38, 419.	3.5	70

#	Article	IF	Citations
37	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). European Journal of Cancer, 2019, 121, 144-153.	1.3	27
38	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). European Journal of Cancer, 2019, 119, 168-178.	1.3	61
39	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2019, 381, 1535-1546.	13.9	2,484
40	NKâ€•and Tâ€¢cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of antiâ€CTLAâ€4 therapy. International Journal of Cancer, 2019, 145, 2238-2248.	2.3	31
41	Genomic Features of Exceptional Response in Vemurafenib Â± Cobimetinibâ€“treated Patients with BRAFV600-mutated Metastatic Melanoma. Clinical Cancer Research, 2019, 25, 3239-3246.	3.2	32
42	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. Clinical Cancer Research, 2019, 25, 7351-7362.	3.2	61
43	The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology. Cancer Immunology, Immunotherapy, 2019, 68, 143-150.	2.0	1
44	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncology, The, 2018, 19, 510-520.	5.1	183
45	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. New England Journal of Medicine, 2018, 378, 1789-1801.	13.9	1,441
46	Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutationâ€“positive melanoma. British Journal of Cancer, 2018, 118, 777-784.	2.9	19
47	Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13â€“15, 2016. Cancer Immunology, Immunotherapy, 2018, 67, 1023-1030.	2.0	3
48	New horizons from immunotherapy in malignant pleural mesothelioma. Journal of Thoracic Disease, 2018, 10, S322-S332.	0.6	8
49	Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy. Frontiers in Pharmacology, 2018, 9, 1443.	1.6	20
50	Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respiratory Medicine,the, 2018, 6, 451-460.	5.2	185
51	Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge. Cancer Immunology, Immunotherapy, 2018, 67, 1317-1324.	2.0	4
52	Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy. Expert Opinion on Biological Therapy, 2018, 18, 77-83.	1.4	13
53	Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts. Journal of Translational Medicine, 2018, 16, .	1.8	2
54	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet, The, 2018, 391, 2128-2139.	6.3	1,487

#	Article	IF	Citations
55	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2017, 18, 393-403.	5.1	91
56	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. European Journal of Cancer, 2017, 73, 61-70.	1.3	88
57	Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. Endocrine, 2017, 58, 535-541.	1.1	33
58	Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. OncoImmunology, 2017, 6, e1323618.	2.1	42
59	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncology, The, 2017, 18, 611-622.	5.1	428
60	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. New England Journal of Medicine, 2017, 377, 1824-1835.	13.9	1,752
61	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2017, 377, 1345-1356.	13.9	3,589
62	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncology, The, 2017, 18, 1261-1273.	5.1	356
63	Immunotherapy targeting immune check-point(s) in brain metastases. Cytokine and Growth Factor Reviews, 2017, 36, 33-38.	3.2	8
64	Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences. Cytokine and Growth Factor Reviews, 2017, 36, 25-31.	3.2	8
65	Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT). Cytokine and Growth Factor Reviews, 2017, 36, 1-3.	3.2	1
66	Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clinical Cancer Research, 2017, 23, 1929-1936.	3.2	290
67	Implementing liquid biopsies into clinical decision making for cancer immunotherapy. Oncotarget, 2017, 8, 48507-48520.	0.8	63
68	Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors. Cancer Research, 2017, 77, CT039-CT039.	0.4	6
69	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clinical Cancer Research, 2016, 22, 5487-5496.	3.2	480
70	ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies. Methods in Molecular Biology, 2016, 1393, 133-139.	0.4	2
71	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. New England Journal of Medicine, 2016, 375, 1845-1855.	13.9	1,140
72	Melanoma and immunotherapy bridge 2015. Journal of Translational Medicine, 2016, 14, 65.	1.8	12

#	Article	IF	Citations
73	Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study. OncoImmunology, 2016, 5, e1071007.	2.1	21
74	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research, 2016, 22, 2908-2918.	3.2	459
75	â€œCancer Bio-Immunotherapy in Sienaâ€: Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9â€“11, 2014. Cancer Immunology, Immunotherapy, 2016, 65, 119-126.	2.0	0
76	Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. Journal of Clinical Investigation, 2016, 126, 921-937.	3.9	71
77	Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy. Vaccines, 2015, 3, 420-428.	2.1	14
78	The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival. Seminars in Oncology, 2015, 42, 387-401.	0.8	24
79	Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunology, Immunotherapy, 2015, 64, 999-1009.	2.0	138
80	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 2015, 373, 23-34.	13.9	6,773
81	Immune Checkpoint Inhibitors in Melanoma Provide the Cornerstones for Curative Therapies. Seminars in Oncology, 2015, 42, 429-435.	0.8	68
82	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Research, 2015, 25, 208-224.	5.7	143
83	Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Annals of Oncology, 2015, 26, 798-803.	0.6	118
84	Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncology, The, 2015, 16, 15-17.	5.1	10
85	Nivolumab in Previously Untreated Melanoma withoutBRAFMutation. New England Journal of Medicine, 2015, 372, 320-330.	13.9	4,795
86	â€œCancer Bio-Immunotherapy in Sienaâ€: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17â€“19, 2013. Cancer Immunology, Immunotherapy, 2015, 64, 131-135.	2.0	0
87	Immune Checkpoint Blockade in Malignant Mesothelioma. Seminars in Oncology, 2015, 42, 418-422.	0.8	8
88	Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respiratory Medicine,the, 2015, 3, 301-309.	5.2	185
89	coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutationâ€“positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519). Journal of Translational Medicine, 2015, 13, O4.	1.8	10
90	Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma. Journal of Translational Medicine, 2015, 13, .	1.8	12

#	Article	IF	Citations
91	Immunologic Checkpoints for Cancer Treatment: A Continuing Success. Seminars in Oncology, 2015, 42, 362.	0.8	0
92	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2015, 16, 375-384.	5.1	2,353
93	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC) Tj ETQq1 1 0.784314 rgBT /Ove	5.1	1,093
94	Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. Journal of Clinical Oncology, 2015, 33, 1191-1196.	0.8	445
95	Epigenetics Meets Immune Checkpoints. Seminars in Oncology, 2015, 42, 506-513.	0.8	32
96	Vemurafenib inBRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. Future Oncology, 2015, 11, 1355-1362.	1.1	6
97	Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. OncoImmunology, 2015, 4, e1019978.	2.1	61
98	Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy. Clinical Cancer Research, 2015, 21, 4040-4047.	3.2	89
99	CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?. Cancer Immunology, Immunotherapy, 2015, 64, 105-112.	2.0	18
100	A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.. Journal of Clinical Oncology, 2015, 33, TPS9090-TPS9090.	0.8	5
101	Peptide-based vaccines for cancer therapy. Human Vaccines and Immunotherapeutics, 2014, 10, 3175-3178.	1.4	59
102	Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program. Cancer Investigation, 2014, 32, 144-149.	0.6	90
103	Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-Aâ€“Specific T Cells. Clinical Cancer Research, 2014, 20, 1601-1609.	3.2	222
104	Longitudinal Study of Recurrent Metastatic Melanoma Cell Lines Underscores the Individuality of Cancer Biology. Journal of Investigative Dermatology, 2014, 134, 1389-1396.	0.3	3
105	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treatment Reviews, 2014, 40, 1056-1064.	3.4	178
106	Epigenetic Markers of Prognosis in Melanoma. Methods in Molecular Biology, 2014, 1102, 481-499.	0.4	6
107	A randomized, openâ€label clinical trial of tasisulam sodium versus paclitaxel as secondâ€line treatment in patients with metastatic melanoma. Cancer, 2014, 120, 2016-2024.	2.0	19
108	Immune checkpoint blockade in malignant mesothelioma. OncoImmunology, 2014, 3, e27482.	2.1	17

#	Article	IF	Citations
109	Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma. Clinical Cancer Research, 2014, 20, 4390-4399.	3.2	36
110	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. Journal of Neuro-Oncology, 2014, 118, 109-116.	1.4	103
111	Epigenetic drugs as immunomodulators for combination therapies in solid tumors. , 2014, 142, 339-350.		92
112	Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. New England Journal of Medicine, 2014, 371, 1867-1876.	13.9	1,824
113	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. Journal of Experimental and Clinical Cancer Research, 2014, 33, 30.	3.5	97
114	Towards the introduction of the â€˜Immunoscoreâ€™ in the classification of malignant tumours. Journal of Pathology, 2014, 232, 199-209.	2.1	1,151
115	Clinical experience with ipilimumab 3Âmg/kg: real-world efficacy and safety data from an expanded access programme cohort. Journal of Translational Medicine, 2014, 12, 116.	1.8	149
116	Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncology, The, 2014, 15, 323-332.	5.1	890
117	Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2014, 15, 700-712.	5.1	1,280
118	Biomarkers for immune checkpoint inhibitors â€“ Authors' reply. Lancet Oncology, The, 2014, 15, e1-e2.	5.1	3
119	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. European Journal of Cancer, 2014, 50, 121-127.	1.3	149
120	A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients.. Journal of Clinical Oncology, 2014, 32, 7531-7531.	0.8	6
121	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.. Journal of Clinical Oncology, 2014, 32, LBA9008-LBA9008.	0.8	14
122	BRIM8: A phase III, randomized, double-blind, placebo-controlled study of vemurafenib adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence (NCT01667419).. Journal of Clinical Oncology, 2014, 32, TPS9118-TPS9118.	0.8	4
123	The Italian Network for Tumor Biotherapy (NIBIT): past, present and future goals. Reviews in Health Care, 2014, 5, 3-6.	0.1	2
124	Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. Cancer Immunology, Immunotherapy, 2013, 62, 897-908.	2.0	31
125	Immunomodulatory activity of SGI-110, a 5-aza-2â€²-deoxycytidine-containing demethylating dinucleotide. Cancer Immunology, Immunotherapy, 2013, 62, 605-614.	2.0	61
126	Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2013, 31, 616-622.	0.8	720

#	Article	IF	Citations
127	Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. Journal of Translational Medicine, 2013, 11, 202.	1.8	31
128	Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10Âmg/kg within an expanded access programme. Cancer Immunology, Immunotherapy, 2013, 62, 1021-1028.	2.0	121
129	Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncology, The, 2013, 14, 1104-1111.	5.1	326
130	Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. Journal of Clinical Oncology, 2013, 31, 2413-2420.	0.8	188
131	Update on the role of ipilimumab in melanoma and first data on new combination therapies. Current Opinion in Oncology, 2013, 25, 166-172.	1.1	27
132	Clinical and immunologic responses in melanoma patients vaccinated with MAGEâ€A3â€genetically modified lymphocytes. International Journal of Cancer, 2013, 132, 2557-2566.	2.3	20
133	Epigenetics of melanoma: implications for immune-based therapies. Immunotherapy, 2013, 5, 1103-1116.	1.0	18
134	Diagnostic and Therapeutic Approaches in Italian Hospitals: Adjuvant and Metastatic Therapy in Melanoma. Dermatology, 2013, 226, 22-27.	0.9	4
135	Clinical experience with ipilimumab 10Âmg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. Journal of Experimental and Clinical Cancer Research, 2013, 32, 82.	3.5	23
136	Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials.. Journal of Clinical Oncology, 2013, 31, 9053-9053.	0.8	12
137	Ipilimumab (Ipi) retreatment at 10 mg/kg in patients with metastatic melanoma previously treated in phase II trials.. Journal of Clinical Oncology, 2013, 31, 9059-9059.	0.8	4
138	Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis. Journal of Clinical Oncology, 2012, 30, 1835-1841.	0.8	112
139	Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class Iâ€“Modified Peptides. Clinical Cancer Research, 2012, 18, 6485-6496.	3.2	61
140	Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. Journal of Translational Medicine, 2012, 10, 185.	1.8	49
141	Cancer classification using the Immunoscore: a worldwide task force. Journal of Translational Medicine, 2012, 10, 205.	1.8	676
142	The role of BRAF V600 mutation in melanoma. Journal of Translational Medicine, 2012, 10, 85.	1.8	563
143	Thymosin Î±1 in melanoma: from the clinical trial setting to the daily practice and beyond. Annals of the New York Academy of Sciences, 2012, 1270, 8-12.	1.8	14
144	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncology, The, 2012, 13, 879-886.	5.1	273

#	Article	IF	Citations
145	The cost of unresectable stage III or stage IV melanoma in Italy. Journal of Experimental and Clinical Cancer Research, 2012, 31, 91.	3.5	25
146	Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunology, Immunotherapy, 2012, 61, 41-48.	2.0	118
147	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF^{V600E}-mutated melanoma.. Journal of Clinical Oncology, 2012, 30, 8502-8502.	0.8	86
148	The biology of cancer testis antigens: Putative function, regulation and therapeutic potential. Molecular Oncology, 2011, 5, 164-182.	2.1	281
149	Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 2011, 9, 214.	1.8	139
150	Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. New England Journal of Medicine, 2011, 364, 2517-2526.	13.9	4,074
151	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine, 2011, 364, 2507-2516.	13.9	6,976
152	Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunology, Immunotherapy, 2011, 60, 467-477.	2.0	79
153	Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. Journal of Translational Medicine, 2011, 9, 78.	1.8	52
154	Expression and regulation of B7â€H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: Immunotherapeutic implications. Journal of Cellular Physiology, 2011, 226, 2595-2600.	2.0	17
155	Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clinical Cancer Research, 2011, 17, 3064-3076.	3.2	108
156	CD40 Expression by Human Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting With the Therapeutic Anti-CD40 Antibody CP-870,893. Journal of Immunotherapy, 2010, 33, 810-816.	1.2	20
157	Cancer testis antigens and melanoma stem cells: new promises for therapeutic intervention. Cancer Immunology, Immunotherapy, 2010, 59, 487-488.	2.0	5
158	Biology and Clinical Applications of CD40 in Cancer Treatment. Seminars in Oncology, 2010, 37, 517-523.	0.8	41
159	Clinical Studies With Antiâ€“CTLA-4 Antibodies in Non-melanoma Indications. Seminars in Oncology, 2010, 37, 460-467.	0.8	52
160	The Emerging Toxicity Profiles of Antiâ€“CTLA-4 Antibodies Across Clinical Indications. Seminars in Oncology, 2010, 37, 499-507.	0.8	224
161	Antiâ€“CTLA-4 Antibody Adjuvant Therapy in Melanoma. Seminars in Oncology, 2010, 37, 455-459.	0.8	37
162	Brain Metastasis in Melanoma: Clinical Activity of CTLA-4 Antibody Therapy. Seminars in Oncology, 2010, 37, 468-472.	0.8	33

#	Article	IF	Citations
163	Introduction to Immunologic Checkpoints for Cancer Treatment: From Scientific Rationale to Clinical Application. Seminars in Oncology, 2010, 37, 429.	0.8	2
164	Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. Journal of Cellular Physiology, 2010, 223, 352-358.	2.0	19
165	CXCR6, a Newly Defined Biomarker of Tissue-Specific Stem Cell Asymmetric Self-Renewal, Identifies More Aggressive Human Melanoma Cancer Stem Cells. PLoS ONE, 2010, 5, e15183.	1.1	65
166	Large Randomized Study of Thymosin Î± 1, Interferon Alfa, or Both in Combination With Dacarbazine in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2010, 28, 1780-1787.	0.8	62
167	Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovascular Research, 2010, 86, 12-19.	1.8	147
168	Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. Journal of Translational Medicine, 2010, 8, 56.	1.8	94
169	High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients. PLoS ONE, 2009, 4, e5219.	1.1	806
170	Epigenetically regulated tumor-associated antigens in melanoma. Expert Review of Dermatology, 2009, 4, 145-154.	0.3	1
171	Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clinical Cancer Research, 2009, 15, 7412-7420.	3.2	2,857
172	Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunology, Immunotherapy, 2009, 58, 1297-1306.	2.0	246
173	Cancer testis antigens in human melanoma stem cells: Expression, distribution, and methylation status. Journal of Cellular Physiology, 2008, 215, 287-291.	2.0	56
174	A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". Journal of Translational Medicine, 2008, 6, 81.	1.8	45
175	Conservation of Genetic Alterations in Recurrent Melanoma Supports the Melanoma Stem Cell Hypothesis. Cancer Research, 2008, 68, 122-131.	0.4	42
176	The Italian Network for Tumor Biotherapy (NIBIT). Sharing Visions, Goals and Efforts at European Level. Tumori, 2008, 94, 179-181.	0.6	3
177	Endoglin (CD105): A Strong Candidate for Immunologic Targeting of Tumor Neovasculature in Human Malignancies. , 2008, , 395-410.		0
178	Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2â€²-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications. Clinical Cancer Research, 2007, 13, 3333-3338.	3.2	120
179	5-AZA-2â€²-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story. Cancer Research, 2007, 67, 2900-2900.	0.4	21
180	Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications. Journal of Cellular Physiology, 2007, 212, 330-344.	2.0	124

#	Article	IF	Citations
181	A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-Î± in metastatic melanoma patients. Cancer Immunology, Immunotherapy, 2006, 55, 958-968.	2.0	134
182	Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: Immunotherapeutic implications. Journal of Cellular Physiology, 2006, 207, 58-66.	2.0	52
183	Is it the primetime for endoglin (CD105) in the clinical setting?. Cardiovascular Research, 2006, 69, 781-783.	1.8	12
184	The Coincidence of Chromosome 15 Aberrations and Î²2-Microglobulin Gene Mutations Is Causative for the Total Loss of Human Leukocyte Antigen Class I Expression in Melanoma. Clinical Cancer Research, 2006, 12, 3297-3305.	3.2	39
185	Epigenetic Modulation of Solid Tumors as a Novel Approach for Cancer Immunotherapy. Seminars in Oncology, 2005, 32, 473-478.	0.8	44
186	Epigenetic Immunomodulation of Hematopoietic Malignancies. Seminars in Oncology, 2005, 32, 503-510.	0.8	17
187	Introduction: Cancer Epigenetics and Epigenetic Treatment of Cancer. Seminars in Oncology, 2005, 32, 435-436.	0.8	0
188	Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: Immunotherapeutic implications. Journal of Cellular Physiology, 2005, 202, 474-477.	2.0	23
189	Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma and peritoneal fluid from ovarian cancer patients. Women's Oncology Review, 2005, 5, 19-21.	0.0	159
190	Heat Shock Proteins and Their Use as Anticancer Vaccines. Clinical Cancer Research, 2004, 10, 8142-8146.	3.2	62
191	Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2â€²-deoxycytidine. Cancer Research, 2004, 64, 9167-9171.	0.4	193
192	Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunology, Immunotherapy, 2004, 53, 227-233.	2.0	116
193	Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma. Journal of Cellular Physiology, 2004, 200, 272-276.	2.0	7
194	Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. Journal of Translational Medicine, 2004, 2, 18.	1.8	139
195	Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?. Journal of Translational Medicine, 2004, 2, 21.	1.8	4
196	Methylation-regulated expression of HLA class I antigens in melanoma. International Journal of Cancer, 2003, 105, 430-431.	2.3	41
197	Differential levels of soluble endoglin (CD105) in myeloid malignancies. Journal of Cellular Physiology, 2003, 194, 171-175.	2.0	48
198	Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene, 2003, 22, 6557-6563.	2.6	222

#	Article	IF	Citations
199	Epigenetic targets for immune intervention in human malignancies. Oncogene, 2003, 22, 6484-6488.	2.6	68
200	Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?. Oncogene, 2003, 22, 6564-6569.	2.6	46
201	Biomolecular strategies for therapeutic intervention in cancer. Oncogene, 2003, 22, 6469-6469.	2.6	0
202	Analysis of Cancer/Testis Antigens in Sporadic Medullary Thyroid Carcinoma: Expression and Humoral Response to NY-ESO-1. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 748-754.	1.8	61
203	5-Aza-2â€²-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?. Blood, 2003, 101, 4644-4646.	0.6	78
204	Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings. Journal of Clinical Oncology, 2002, 20, 4169-4180.	0.8	361
205	Promoter Methylation Controls the Expression of MAGE2, 3 and 4 Genes in Human Cutaneous Melanoma. Journal of Immunotherapy, 2002, 25, 16-26.	1.2	111
206	Introduction: Melanoma: American and European perspectives on diagnosis and treatment. Seminars in Oncology, 2002, 29, 306-307.	0.8	0
207	European approach to antibody-based immunotherapy of melanoma. Seminars in Oncology, 2002, 29, 471-478.	0.8	3
208	Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells*. Journal of Cellular Physiology, 2002, 190, 200-206.	2.0	7
209	Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunology, Immunotherapy, 2002, 51, 9-14.	2.0	38
210	5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clinical Cancer Research, 2002, 8, 2690-5.	3.2	114
211	Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignangies. Frontiers in Bioscience - Landmark, 2001, 6, d776.	3.0	6
212	Unbalanced expression of HLA-A and -B antigens: A specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN-?. International Journal of Cancer, 2001, 91, 500-507.	2.3	10
213	Endoglin: An accessory component of the TGF-?-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. Journal of Cellular Physiology, 2001, 188, 1-7.	2.0	162
214	Unbalanced expression of HLAâ€A and â€B antigens: A specific feature of cutaneous melanoma and other nonâ€hemopoietic malignancies reverted by IFNâ€î³. International Journal of Cancer, 2001, 91, 500-507.	2.3	1
215	Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement. Journal of Cellular Physiology, 2000, 185, 317-323.	2.0	26
216	Vaccination of Melanoma Patients with Interleukin 4 Gene-Transduced Allogeneic Melanoma Cells. Human Gene Therapy, 1999, 10, 2907-2916.	1.4	61

#	Article	IF	Citations
217	Differential levels of soluble intercellular adhesion molecule-1 (sICAM-1) in early breast cancer and benign breast lesions. Breast Cancer Research and Treatment, 1999, 58, 19-23.	1.1	19
218	In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells. Cancer Immunology, Immunotherapy, 1999, 48, 132-138.	2.0	8
219	The overlooked ?nonclassical? functions of major histocompatibility complex (MHC) class II antigens in immune and nonimmune cells. Journal of Cellular Physiology, 1999, 179, 251-256.	2.0	19
220	Prolonged Upregulation of the Expression of HLA Class I Antigens and Co stimulatory Molecules on Melanoma Cells Treated with 5-aza-2??-deoxycytidine (5-AZA-CdR). Journal of Immunotherapy, 1999, 22, 16-24.	1.2	119
221	Pregnancy and Malignant Neoplasms of the Head and Neck. Annals of Otology, Rhinology and Laryngology, 1998, 107, 991-998.	0.6	22
222	Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. Cancer Immunology, Immunotherapy, 1997, 44, 197-203.	2.0	67
223	Limited Antitumor T Cell Response in Melanoma Patients Vaccinated with Interleukin-2 Gene-Transduced Allogeneic Melanoma Cells. Human Gene Therapy, 1996, 7, 1955-1963.	1.4	83
224	Melanoma-Associated Hypopigmentation: Where Are the Antibodies?. American Journal of Clinical Oncology: Cancer Clinical Trials, 1996, 19, 613-618.	0.6	18
225	Signaling by HLA class II antigens on B cells. Trends in Immunology, 1995, 16, 548.	7.5	4
226	Expression and Functional Role of CD54/Intercellular Adhesion Molecule-1 (ICAM-1) on Human Blood Cells. Leukemia and Lymphoma, 1992, 8, 23-33.	0.6	31
227	Modulation by cytokines of HLA antigens, intercellular adhesion molecule 1 and high molecular weight melanoma associated antigen expression and of immune lysis of clones derived from the melanoma cell line MeM 50-10. Cancer Immunology, Immunotherapy, 1989, 30, 34-42.	2.0	8
228	Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells. International Journal of Cancer, 1989, 44, 554-559.	2.3	28
229	HLA and prognostic factors in primary breast cancer. International Journal of Cancer, 1985, 35, 581-585.	2.3	12
230	The Association Between Congenital Adrenal Hyperplasia and HLA in Southern Italy. Annals of the New York Academy of Sciences, 1985, 458, 46-51.	1.8	3
231	MODULATION OF HLA-DR ANTIGENS EXPRESSION IN HUMAN MYELOID LEUKAEMIA CELLS BY CYTARABINE AND 5-AZA-2'-DEOXYCYTIDINE. Lancet, The, 1984, 324, 867-868.	6.3	59
232	Strong association between an HLAâ€ÐR antigen and thyroid carcinoma. Tissue Antigens, 1982, 20, 155-158.	1.0	45